Interplay between long non-coding RNAs and epigenetic machinery: emerging targets in cancer?

David J. Hanly¹, Manel Esteller¹,²,³ and Maria Berdasco¹

¹Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain
²Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Spain
³Institució Catalana de Recerca i Estudis Avançats (ICREA), 08908 Barcelona, Spain

Of the diverse array of putative molecular and biological functions assigned to long non-coding RNAs (lncRNAs), one attractive perspective in epigenetic research has been the hypothesis that lncRNAs directly interact with the proteins involved in the modulation of chromatin conformation. Indeed, epigenetic modifiers are among the most frequent protein partners of lncRNAs that have been identified to date, of which histone methyltransferases and protein members of the Polycomb Repressive Complex PRC2 have received considerable attention. This review is focused on how lncRNAs interface with epigenetic factors to shape the outcomes of crucial biological processes such as regulation of gene transcription, modulation of nuclear architecture, X inactivation in females and pre-mRNA splicing. Because of our increasing knowledge of their role in development and cellular differentiation, more research is beginning to be done into the deregulation of lncRNAs in human disorders. Focusing on cancer, we describe some key examples of disease-focused lncRNA studies. This knowledge has significantly contributed to our ever-improving understanding of how lncRNAs interact with epigenetic factors of human disease, and has also provided a plethora of much-needed novel prognostic biomarker candidates or potential therapeutic targets. Finally, current limitations and perspectives on lncRNA research are discussed here.

This article is part of a discussion meeting issue ‘Frontiers in epigenetic chemical biology’.

1. Introduction

While less than 2% of the human genome has protein-coding potential, over 70% of it can undergo transcription, meaning that most of the human transcriptome consists of non-coding RNA (ncRNA) [1]. The non-coding transcriptome can be conceptualized in terms of the varying sizes of non-coding transcripts, ranging from the shorter miRNAs and piRNAs of below 40 bp, through mid-sized snRNAs (60–300 bp) and enhancer RNAs (eRNA; 50–2000 bp) [2], to long non-coding RNAs (lncRNAs), a highly diverse group of transcripts that are all over 200 bp in length [3]. These can be further stratified into long intergenic ncRNA (lincRNAs), transcribed ultra-conserved regions (T-UCRs), natural antisense transcripts (NATs) and large intronic ncRNAs, among others. In quantity, lncRNAs outnumber protein-coding genes, yet it remains the case that relatively few of the nearly 60,000 human IncRNA genes [4] have been studied and characterized in significant detail. Nonetheless, over the past two decades, they have been linked to a wide range of molecular biological processes, ranging from nucleus-specific roles in modulating transcription, epigenetic modification,
DNA looping and nuclear compartment formation, to involvement in alternative splicing and miRNA network cross-talk [5].

2. Long non-coding RNA cross-talk with epigenetic factors

Of the functions assigned to IncRNAs, perhaps the crucial one from the perspective of epigenetics researchers has been the hypothesis that IncRNAs directly interact with the writers, readers and erasers of histones [6]. Thus, IncRNAs may direct and determine the specific subnuclear domains and genetic loci at which the histone-modifying machinery acts in any given cell type [7]. They could also serve as molecular scaffolds of specific chromatin-regulatory complexes, combining and integrating the molecular functions of multiple histone modifiers along with other types of chromatin-regulatory machinery, thereby fine-tuning both the lower- and higher-order chromatin structure of a given target locus [8]. This section, summarized in table 1, will provide an overview of how IncRNAs shape the outcomes of gene transcription, nuclear architecture and pre-mRNA splicing.

| IncRNA        | functional effects                                                                 | references |
|---------------|------------------------------------------------------------------------------------|------------|
| Xist          | histone modification complex recruitment  
histone modification (H3K27 deacetylation; H3K27me3; H2AK119ub)  
gene silencing  
heterochromatin formation  
nuclear architecture remodelling  
X chromosome compaction | [7–14]     |
| HOTAIR        | histone modification complex scaffolding  
histone modification (H3K4 demethylation, H3K27me3)  
gene silencing | [15–17]    |
| ANRIL         | PcG histone modification complex recruitment  
histone modification (H3K27me3; H2AK119ub)  
gene silencing | [18,19]    |
| KCNQ1OT1      | histone modification complex recruitment (G9a, PRC2)  
histone modification (H3K9me3, H3K27me3)  
locus silencing | [20,21]    |
| AIR           | G9a recruitment  
H3K9me3  
gene silencing | [22,23]    |
| HOTTIP        | histone modification complex recruitment (WRD/MLL)  
histone modification (H3K4me3)  
gene activation | [24]       |
| CCND1-NAT     | recruitment and activation of HAT inhibitor (TLS)  
gene activation | [25]       |
| eCEBPA        | DNMT1 inhibition  
gene activation | [26]       |
| Dali          | trans inhibition of DNMT1  
gene activation | [27]       |
| lincRNA-p21   | hnRNP-K interaction; DNMT1 interaction  
p53 target gene silencing | [28,29]    |
| Firre         | nuclear architecture remodelling  
escape from X inactivation | [7]        |
| MALAT1        | nuclear body formation  
splicing factor sequestration  
localization to sites of active transcription | [30,31]    |
| MIAT          | Gomafu body formation  
splicing factor sequestration | [32–34]    |
The origins of the hypothesis that IncRNAs guide histone modifiers to modulate the epigenetic control of gene transcription can be traced back to earlier breakthrough studies on the process of X chromosome inactivation (XCI) [9,35]. Wutz et al. [10] first found that an ORFless transcript, termed Xist, is transcribed from the X-inactivation centre (Xic) and retained in the nucleus to act as the master cis-acting regulator of XCI. Convergently, Polycomb Repressive Complex 2 (PRC2) was found to be responsible for H3K27me3 enrichment in the Xi [36], and PRC2 recruitment to the Xi was shown to depend on Xist expression [37]. From these findings emerged the idea that Xist may guide PRC2-mediated gene repression on the Xi. Recent studies characterizing the Xist complex led to the definition of a stepwise model of the Xist molecular mechanism of XCI coordination [8]. This silencing process involves interactions with several chromatin remodelers, including the DNA-/RNA-binding protein SAFA, the binding protein SHARP and histone deacetylase 3 (HDAC3) and PRC1/PRC2 complexes [11,15,38].

As the decade progressed, interest in the idea of RNA-guided gene regulation broadened following a study on HOX gene transcriptional regulation [16]. Rinn et al. [16] demonstrated that an IncRNA transcribed from the HOXC locus, named HOTAIR, represses the HOXD locus in trans and in doing so recruits PRC2 to the locus to establish repressive chromatin mark H3K27me3. Tsai et al. [39] later observed that HOTAIR directly interacts not only with PRC2 at its 5’-end but also with H3K4-targeting demethylase LSD1. In parallel, two independent studies found that PRC2 alone binds to approximately 24% of transcripts genome-wide, demonstrating that a genome-wide RNA family may direct PRC2 to its target genes. These findings widened the scope of the hypothesis of IncRNA involvement in modulating chromatin modifications, establishing its potential as a global epigenetic regulatory mechanism [18,40].

Another functionally related IncRNA implicated in the epigenetic control of gene expression is known as ANRIL [19]. It is transcribed antisense to the INK4b(p15)-ARF(p14)-INK4a(p16) cluster of tumour suppressor genes, a locus subject to stringent regulation by both PRC1 and PRC2 components. Upon its transcription, ANRIL is thought to act in cis to recruit PRC2 via direct binding to the SUZ12 subunit to direct H3K27 trimethylation of the locus. ANRIL also recruits PRC1 by interacting with its CBX7 subunit, and CBX7 in turn binds H3K27me3, which stimulates H2AK199 ubiquitination by PRC1 [19,41].

The imprinted IncRNA KCNQ1OT1 was found to interact with PRC2 components EZH2 and SUZ12, as well as with G9a, to mediate in cis silencing of a 200 kb locus surrounding its transcription site in a lineage-specific manner [20]. Partial deletion of an 890 bp region of KCNQ1OT1 on the paternal allele, from which the IncRNA itself is exclusively expressed, resulted in the loss of paternal allele-specific gene repression of ubiquitously imprinted locus genes and reduced CpG methylation of the differentially methylated regions of these genes. It has been proposed to mediate paternal-specific Kcnql locus methylation by interacting with DNA methyltransferase 1 (DNMT1), as DNMT1 occupies the same ubiquitously imprinted genes and the 890 bp region of KCNQ1OT1 was shown to be necessary for co-immunoprecipitation of KCNQ1OT1 with DNMT1 [22].

IncRNA Air is another imprinted IncRNA specifically expressed from the paternal allele [25]. It is transcribed antisense to Igf2r and in embryos is necessary for the repression of Igf2r in cis, as well as for Slc22a2 and Slc22a3 silencing in the placenta. Air was found to preferentially accumulate at the Slc22a3 promoter in mouse placental tissue [25]. It interacts with G9a, a necessary factor for Slc22a3 silencing; thus, Air appears to recruit G9a to target H3K9 methylation at the promoter, thereby repressing Slc22a3 expression [25].

A further locus-specific example of ncRNA-modulated gene silencing was revealed in a study by Wang et al. [24], in which it was found that ncRNA transcribed upstream of the CCND1 gene upon DNA damage induction recruits TLS (Translocated in Liposarcoma) to the promoter region and allosterically releases it from its inactive conformation, enabling it to inhibit histone acetyltransferase (HAT) CBP/p300 and thus repress CCND1 transcription [24].

As for IncRNAs with potential roles in mediating gene activation, the best example, to date, is perhaps HOTTIP, which is transcribed from the HOXA locus and is responsible for the activation of several HOXA genes through the recruitment of the WRD5/ML histone methyltransferase (HMT) complex, which in turn facilitates gene activation by tri-methylating H3K4 at the HOXA promoter [42]. Recently, eRNAs have also been found to interact with the CBP/p300 HAT complexes bound to enhancers, stimulating CBP HAT activity to increase H3K27ac levels at both the enhancer and the promoter of its target gene, which leads to target gene expression activation [26].

In addition to mediating histone modification, IncRNAs have also been found to directly influence DNA methylation. A novel IncRNA that is sense-transcribed from upstream of the CEPBA gene and that also encompasses the entire protein-coding mRNA sequence but itself remains in the nucleus has been described [28]; thereafter, it was called ‘extra-coding’ CEPBA (ecCEPBA), and it was found that it selectively inhibits DNA methylation of the CEPBA promoter [28]. This was due to its direct interaction with DNMT1, which has a higher affinity for ecCEPBA than for the CEPBA CpG island. Another group identified IncRNA-p21 as a barrier to the reprogramming of pre-induced pluripotent cells (pre-iPSCs) to iPSCs. LinRNA-p21 is induced by p53 and functions by interacting with H3K9 histone methyltransferase SETDB1 and with DNMT1. It directs these epigenetic modifiers to repress pluripotency genes by trimethylating H3K9 and methylating CpG islands within the target gene promoters [43].

A particularly unique IncRNA, telomere repeat-containing RNA (TERRA), is transcribed from telomeres and regulates telomere maintenance and function through a plurality of integrated mechanisms in a cell cycle-dependent manner (reviewed in greater depth elsewhere [44,45]). Among these mechanisms, TERRA has been proposed to act in part as a scaffold of heterochromatin-associated proteins at chromosome ends, including Shelterin complex components TRF1 and TRF2, heterochromatin protein HP1α and H3K9 HMT SUV39H1, in order to facilitate telomeric heterochromatin formation [30,32,46].
4. Long non-coding RNAs involved in nuclear architecture and three-dimensional genome structure

Recent proteomic studies of Xist interactors have also made progress in the mechanistic integration of its base-level epigenetic cross-talk with their role in the unique rearrangement of X chromosomal higher-order chromatin structure [8]. While the active X chromosome (Xa) normally assumes a distinct three-dimensional structure consisting of several topologically associated domains, Xi is compacted into two mega-domains that are fixed to the nuclear lamina, except for several megaloops that escape XCI silencing and establish transcriptionally active foci [33]. Beginning with the establishment of gene silencing and chromatin compaction at its own locus, Xist establishes the higher-order restructuring of the Xi by first spreading to sites immediately proximal to its locus, forming the compacted, expansive Xist-coated inactive X chromatin territory that grows by drawing initially distal transcriptionally active regions into the silent compartment [33].

Another intriguing recent example of how IncRNAs can modulate the three-dimensional arrangement of the genome is Firre, a nuclear-retained IncRNA that localizes to chromatin both in cis and in trans to form a distinct nuclear compartment that brings into spatial proximity not only target sequences of the X chromosome but also specific loci from chromosomes 2, 9, 15 and 17 [47].

5. Epitranscriptomics of long non-coding RNAs—a nascent field

In a recent study providing a first glimpse of a particularly intriguing novel mechanistic layer of Xist-mediated epigenetic cross-talk, it was found that Xist reversibly undergoes N6-adenosine methylation (m6A). This mark is reportedly added by METTL3 (methyltransferase like 3), which is recruited to Xist via RNA-binding motif protein 15 (RBMP15) and RBMP15B of the Spen family. m6A marks on Xist are, in turn, recognized by YTHDC1 (YTH domain (RBMP15) and RBMP15B of the Spen family. m6A marks on Xist are, in turn, recognized by YTHDC1 (YTH domain containing 1). All of these components appear necessary for Xist-mediated gene silencing, as loss of any of these Xist-interacting proteins leads to the failure of Xist to silence the Xi [48]. However, the mechanism by which this pathway contributes to achieve Xi silencing is unknown, let alone how it cross-talks with the other silencing factors recruited by Xist to initiate and consolidate gene silencing. Therefore, just as it will be necessary to further examine the post-translational modification dynamics of Xist-interacting proteins, so too will it also be important to find new ways of characterizing the presence and dynamics of IncRNA post-transcriptional modifications to form a more precise understanding of how IncRNA cross-talks with epigenetic modifiers.

6. Long non-coding RNAs associated with alternative splicing

Pre-mRNA splicing, which often occurs co-transcriptionally and sensu stricto post-transcriptionally, is more often than not a scenario with multiple possible outcomes that can be mechanistically determined by splice-regulatory factors, histone modifications and chromatin structure [49–51]. Although the molecular processes underlying specific types of alternative splicing event have been characterized in greater detail during the past decade, it is by no means clear how exactly a given splicing outcome is selected and set in motion for any given transcript. However, in addition to regulating the transcriptional activity of genes, IncRNAs can also influence the processing of pre-mRNA [52], and hence could be key players in determining the specific conditions under which alternative transcript isoforms are selected. The best example, to date, of the IncRNA influence on alternative splicing is given by MALAT1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1), which forms a type of nuclear sub-compartment known as the nuclear speckle, and binds various splicing regulatory factors [53] such as SRSF1 [54] and serine/arginine (SR) splice-regulatory factors [54]. MALAT1 depletion leads to increased exon inclusion in most differentially spliced genes identified and showed similar alternative splicing patterns to cells with transient SRSF1 overexpression [54]. It has since been thought that MALAT1, and other splicing factor-interacting IncRNAs, negatively regulate alternative splicing events by sequestering specific splicing factors and restricting their availability to participate in alternative splicing [54,55].

An additional nuclear-retained IncRNA to have emerged during the past decade as a key non-coding player in the regulation of alternative splicing is MIAT (Myocardial Infarction-Associated Transcript) [56] and its mouse homologue Gomafu. It has been found that Gomafu contains a repeat splicing-factor-1 (SFI)-binding motif that facilitates its direct binding to this SF [57], and that oligos mimicking the Gomafu SF1-binding site delayed the onset of splicing of a weak branch point [57]. This result is consistent with the proposed role of SFI as being required for the removal of introns with suboptimal branch points and with the notion that Gomafu restricts SF1 from interacting with sub-optimal branch points. A subsequent study of Gomafu and another splicing factor, Celf-3, provided further evidence for the idea that Gomafu may act as a molecular sponge of splicing factors to restrict their availability in the nucleus, and thereby either delay the kinetics of the splicing events that they coordinate or diminish the frequency of their occurrence [58].

7. Epigenetic long non-coding RNAs and cancer

Much of the impetus behind the renewed efforts of the past decade to understand the role of the non-coding genome in epigenetic cross-talk has been driven by the ongoing need to better characterize human pathologies at the molecular level [3]. Focusing on cancer, this section, summarized in table 2, highlights some key examples of disease-focused IncRNA studies that have significantly contributed to our ever-improving understanding of how IncRNAs cross-talk with epigenetic factors in health and disease, and have also provided a plethora of much-needed novel prognostic biomarkers.

One the most well-studied IncRNAs associated with cancer is HOTAIR. (A comprehensive overview of HOTAIR involvement in multiple tumour types is provided by Bhan & Mandal [89] J. A pioneering metastatic lung cancer study by Gupta et al. [59] found that HOTAIR overexpression increased the invasive capacity of breast cancer cell lines and increased lung metastasis in mouse xenograft models.
| lncRNA   | disease                        | functional effects                                      | tumorigenic effects                      | references     |
|----------|--------------------------------|--------------------------------------------------------|------------------------------------------|----------------|
| HOTAIR   | breast cancer                  | PRC2 recruitment, chromatin modification               | metastasis                               | [59]           |
|          | squamous cell carcinoma (SCC)  | EZH2 recruitment                                      | increased cell proliferation             | [60,61]        |
|          | (oral, oesophageal)            | histone modification (H3K27me23)                      | epitelial–mesenchymal transition         |                |
|          |                                |                                                        | (EMT) activation                         |                |
|          |                                |                                                        | metastasis                               |                |
| osteosarcoma | gene silencing                | DNA methylation regulation                           | cell viability                           | [62]           |
| gastric cancer | gene silencing                |                                                        | evasion of apoptosis                      | [63]           |
| colorectal cancer (CRC) | PRC2 recruitment, chromatin modification (H3K27me3) |                                                        | invasion and metastasis                  | [64]           |
| hepatocellular carcinoma (HCC) | EZH2 recruitment; repressor scaffolding | gene silencing                                      | increased cell viability                 | [65–67]        |
| lung adenocarcinoma (LAD) | gene silencing                |                                                        | evasion of apoptosis                      | [68]           |
| ovarian cancer | not available                 |                                                        | increased proliferation                  | [29,69]        |
| renal cell carcinoma (RCC) | gene activation               |                                                        | invasion and metastasis                  |                |
| glioblastoma | PRC2 recruitment               | increased migration                                    | platinum drug resistance                 |                |
| MALAT1   | lung cancer                    | mediation of oncogenic Oct4 transcriptional reprogramming | increased proliferation                 | [72–74]        |
|          | bladder cancer                 | SUZ12 interaction                                     | metastasis                               | [75]           |
| RCC      | EZH2 interaction; histone modification (H3K27me3) |                                                        | increased cell viability                 | [76]           |
| osteosarcoma | EZH2 interaction               | mediation of TGF-β-driven metastasis                  | evasion of apoptosis                      |                |
| lymphoma | EZH2 interaction, stabilization cell cycle progression |                                                        | metastasis                               |                |
| ANRIL    | gastric cancer                 | PR2 targeting                                          | increased proliferation                  | [80]           |
|          | cervical cancer                | P3 K/AKT pathway activation                           | evasion of apoptosis                      |                |
| lincRNA-p21 | Pan-cancer                    | PR2 targeting                                          | increased proliferation                  | [43,82,83]     |
|          |                                | histone modification (H3K27me3)                        | evasion of apoptosis                      |                |
|          |                                | gene silencing                                         | cell differentiation                     |                |

(Continued.)
Moreover, over 800 genes were newly occupied and repressed by PRC2 following HOTAIR overexpression, including genes known to inhibit breast cancer progression. Indeed, the capacity of HOTAIR to drive breast cancer metastasis was found to depend on the concomitant presence of intact PRC2 [59]. HOTAIR has also been found to be upregulated in human oral squamous cell carcinoma samples in association with a worse prognosis score [60]. In the same study, it was found that HOTAIR enhances metastasis by repressing E-cadherin expression via its association with EZH2 [60].

A later study revealed that HOTAIR also epigenetically regulates the transcription of miRNAs in driving gastric cancer invasion and metastasis, demonstrating that HOTAIR overexpression is associated with cisplatin resistance in an ovarian cancer cell line, and that HOTAIR knockdown sensitized the cell line to cisplatin [69].

MALAT1 owes its name to its discovery as an overexpressed transcript in non-small cell lung cancer (NSCLC) metastases that provided an early-stage marker of NSCLC metastasis risk even before its molecular functions were characterized [72]. It was later demonstrated to be a necessary factor in a mouse xenograft model of NSCLC metastasis, which was proved by employing antisense oligonucleotides (ASOs) to deplete MALAT1 in the xenograft tumours studied [73]. This also gave an early indication of the therapeutic potential of using ASOs against oncogenic lncRNAs in the treatment of lncRNA-associated disease. Its overexpression has also been linked with the invasive capacity of metastatic colorectal cancer cells [91]. Another authoritative study by Tripathi et al. [92] aiming to explore the mechanisms by which MALAT1 may drive oncogenesis found that MALAT1 controls cell cycle progression by modulating cell cycle gene expression, and that MALAT1 is required for the G1/S phase and mitotic progression.

Despite it being principally associated with nuclear body formation and splicing regulation at the fundamental molecular level, accumulating evidence indicates that MALAT1 overexpression contributes towards metastatic tumours predominantly through aberrantly coordinating the epigenetic regulation of gene expression [93]. Moreover, in bladder cancer, overexpressed MALAT1 promotes TGFβ-driven bladder cancer metastasis by directly interacting with PRC2 subunit Suzz12 to repress E-cadherin expression [75]. Consistent with these findings, a direct MALAT1–EZH2 interaction has been implicated in renal cell carcinoma metastasis, as well as in osteosarcoma, as outlined in a recent study that directly linked the metastasis-promoting MALAT1–EZH2 interaction.

Table 2. (Continued.)

| IncRNA  | disease                        | functional effects     | tumorigenic effects          | references |
|---------|--------------------------------|------------------------|----------------------------|------------|
| TBS53G1 | CRC                            | protein sequestration  | increased proliferation      | [84]       |
|         |                                |                        | evasion of apoptosis         |            |
|         |                                |                        | metastasis                  |            |
| DACOR1  | CRC                            | DNMT1 interaction     | increased clonogenic potential | [85]       |
|         |                                | CpG methylation       |                            |            |
|         |                                | gene expression regulation |                       |            |
| TCF7    | HCC                            | SWI/SNF complex recruitment | cancer stem cell (CSC) self-renewal | [86]       |
|         |                                | nucleosome remodelling |                            |            |
|         |                                | gene activation        |                            |            |
| ZEB2-AS | HCC                            | alternative splicing regulation | metastasis         | [12]       |
|         |                                | metastasis gene regulation |                       |            |
|         | chronic lymphocytic leukaemia (CLL) | not available          | increased proliferation     | [87]       |
| MIAT    | chronic lymphocytic leukaemia (CLL) | PrCg gene network modulation | not available          | [87]       |
|         | neuroendocrine prostate cancer (NEPC) |                |                            |            |

That patients whose tumours were ‘HOTAIR expressors’ preferentially responded to cisplatin chemotherapy, an unexpected finding that contradicted another cell-based study demonstrating that HOTAIR overexpression is associated with cisplatin resistance in an ovarian cancer cell line, and that HOTAIR knockdown sensitized the cell line to cisplatin [69].
to E-cadherin epigenetic repression in this tumour type and established MALAT1 as a predictive biomarker of poor survival in osteosarcoma patients [77]. Furthermore, it was recently found that the association of MALAT1 with EZH2 promoted mantle cell lymphoma development, in which MALAT1 overexpression was linked with reduced overall survival. In this study, MALAT1 was found to be responsible for repressing the transcription of cyclin-dependent kinases (CDKs) p21 and p27, which are also targets of EZH2. The interaction of MALAT1 and EZH2 was also found to be enhanced by EZH2 phosphorylation at T350, and the investigators suggested that a MALAT1-mediated positive feedback loop may exist that stabilizes the interaction by promoting T350 phosphorylation of EZH2 [79].

In 2009, Guttman et al. [94] found a cluster of differentially expressed lncRNAs associated with the p53-mediated DNA damage response. One such lncRNA is known as lincRNA-p21, which was found to be necessary to enact the transcriptional regulation of a substantial proportion of p53 target genes [82]. lincRNA-p21 knockdown significantly increased cell viability by reducing apoptosis, whereas its overexpression increased apoptosis following DNA damage induction through direct interaction with the heterogeneous nuclear ribonucleoprotein K (hnRNPK). [82]. hnRNPK and lincRNA-p21 also displayed overlapping target promoter occupancy. Therefore, at least in part, lincRNA-p21 may regulate the expression of its designated branch of the p53-mediated gene regulation programme by modulating hnRNPK localization to lincRNA-p21 target genes [82].

A more recent study revealed a novel tumour suppressor lncRNA that may constitute another important branch of the tumour suppressive p53 network [84]. In searching for novel lncRNAs epigenetically deregulated in cancer, Diaz-Lagares et al. first identified TP53TG1 as being Cpg-hypermethylated in colon cancer cell line HCT-116. Overexpression of TP53TG1 in HCT-116 cells had a tumour suppressive effect both in vitro and in HCT-116 induced mouse tumours that was dependent on the presence of functional p53. Next, RNA pulldown of TP53TG1-bound proteins, combined with mass spectrometry, established that it binds YBX1, a protein with both DNA- and RNA-binding capacity that can participate directly in the regulation of gene transcription [95], pre-mRNA splicing [96] and protein translation [97]. Transfection-mediated TP53TG1 recovery in HCT116 cells reduced the level of YBX1 binding of the PI3 K promoter and, consequently, reduced the abundance of total PI3 K protein and stabilized p53 protein levels. Interestingly, hypermethylation of TP53TG1 promoter and YBX1 nuclear localization in gastric tumour samples were significantly co-associated with worse progression-free patient survival [84].

MIAT has recently been newly implicated in cancer. Sattari et al. [87] found that MIAT is upregulated in aggressive forms of chronic lymphocytic leukaemia (CLL). The study also revealed that MIAT is involved in a positive regulatory feedback loop with Oct4, as suppression of one led to reduced expression of the other [87], consistent with a previous study that characterized the transcriptional regulation of MIAT by Oct4 [98]. This MIAT-Oct4 regulatory loop was also found to directly contribute to apoptosis evasion in CLL, as repression of either significantly induced cell death of malignant B cells. Moreover, in an outline of emerging evidence for the general involvement of the epigenetic/non-coding interactome in neuroendocrine prostate cancer (NEPC), Crea et al. [88] provided preliminary evidence showing that MIAT is upregulated in aggressive NEPC and suggested that it may interact with Polycomb pathways to promote aggressive disease.

An intriguing cancer-associated example of a splice-regulatory lncRNA comes in the form of the metastasis-associated NAT of the gene encoding Zeb2, a transcriptional repressor of E-cadherin and thus a metastasis-coordinating transcription factor. The Zeb2 NAT, known as ZEB2-AS1, is complementary to the sequence of a large Zeb2 intron containing an internal ribosome entry site that is necessary for its translation, and expression of this NAT promotes the retention of this intron in the mRNA by preventing it from being spliced out of the pre-mRNA, which leads to increased Zeb2 protein translation [99]. ZEB2-AS1 has recently been found overexpressed in HCC, and its downregulation in HCC reduced HCC growth and metastasis. In combination with HCC patient data analysis linking high ZEB2-AS1 expression levels with worse progression-free survival, this study indicates its potential utility as an HCC prognosis biomarker [12].

8. Conclusion and perspectives

Unlike genetic defects, epigenetic defects are potentially reversible and are therefore more amenable to corrective therapeutic reversal. This realization has driven the rapid emergence and expansion of epigenetic drug discovery, and drug-targeting epigenetic enzymes are in the clinic for the treatment of human disorders, especially for clinical management of haematological malignancies and neurological disorders [13,14]. However, treatments with epi-drugs still need to overcome the challenge of avoiding off-target effects. It should be considered that multiple epi-enzymes are contained in chromatin complexes, and as a result the inhibition of an epigenetic enzyme can result in changes in other members of the same protein complex. For example, treatment with the HDAC inhibitor sodium butyrate alters the acetylation level of histones, but also affects their methylation status [17]. A new layer of complexity should be taken into account, because lncRNAs could also be regulated by epigenetic mechanisms, including Cpg methylation as well as histone marks [21]. The data gathered so far concerning the involvement of lncRNA in epigenetic regulation are probably still the tip of the iceberg of this emerging field, and further expansion of these data may concomitantly reveal a plethora of as-yet untapped targets and pathways amenable to epigenetic therapy. Therefore, we should consider the reactivation or silencing of specific lncRNAs after treatment with epi-drugs and the secondary effects on their target genes.

As summarized in this review, evidence of the deregulation of lncRNAs in human disorders is rapidly increasing and lncRNAs per se are potential targets of promising therapies. Several advantages support this research. First, lncRNAs provide a solution for targeting underexpressed epigenetic targets. While most epi-drugs produced to date are inhibitors of epigenetic enzymes, which are effective in mitigating the aberrant overexpression of epi-enzymes, success in the development of small-molecule drugs that are able to induce protein activation is very scarce. By inhibiting the expression of any given lncRNA, it is possible to achieve the upregulation of its genetic target(s) [5]. Second, and in clear contrast...
to short ncRNAs, IncRNA expression shows high specificity, because they are expressed at different stages of development and in a cell type-specific manner [23,27]. In addition, IncRNAs normally target one gene or a small group of related genes [5], reducing the number of non-specific targets.

Despite the great potential of targeting IncRNAs, the possibility of manipulating their expression remains largely unexplored. To date, most efforts have been focused on the silencing of specific IncRNAs using synthetic ASOs [31]. This is a very interesting strategy to follow in rare disorders that are normally caused by deficits of specific proteins. Recently, several ASO-based assays have been reported, such as the use of ASOs to re-express the paternal Ube3a allele in Angelman syndrome [34], SCN1A upregulation in Dravet syndrome [100] or the activation of Fratxin expression in Friedrich’s ataxia [101]. While ASO-based IncRNA-targeting strategies are yet to reach clinical trials, MALAT1 has been the best studied IncRNA ASO target in cancer cells in vitro and hence is currently the most feasible IncRNA target for the development of an anti-cancer ASO therapeutic agent [73]. Moreover, if loss of function is caused by epigenetic silencing, a catalytic domain of an epigenetic enzyme fused to the CRISPR/Cas system can be used as an epigenetic editing tool to rewrite the target epigenetic mark at any particular IncRNA locus to re-express it. On the other hand, an overexpressed IncRNA could be silenced by reconfiguring its local chromatin context to repress its expression [102].

Nevertheless, many important questions regarding IncRNA complexity remain to be solved. Given their biological versatility, it is crucial to investigate whether IncRNAs are activated or silenced in any given tissue, and how they exert their respective functions. As previously described in this review, the same IncRNA can participate in several biological processes such as transcription regulation or formation of nuclear compartments. We still need to investigate how IncRNA function could be a consequence of external and internal stimuli.

In summary, the ncRNA world reveals new layers of complexity in the complex epigenetic milieu. Although we are beginning to understand their role as chromatin regulators, new functions are steadily emerging. Studies have revealed IncRNA involvement not only at the transcriptional level but also in processes such as imprinting, alternative splicing and long-range DNA looping, among others. Just as we are advancing in our understanding of IncRNA biology, new IncRNA defects associated with human disorders are being described, opening new avenues for their uses as disease biomarkers and/or therapeutic targets. However, the extent of our current knowledge is greatly limited by methodological limitations. We still need to make progress on the development of appropriate tools to equip researchers to study IncRNA structure and unravel the spatial and developmental specificities of IncRNAs.

Data accessibility. This article has no additional data.

Authors’ contributions. D.J.H., M.E. and M.B. contributed to specific content of the review by preparing the main text. D.J.H. prepared the tables. All the authors read and approved the final manuscript.

Competing interests. We declare we have no competing interests.

Funding. The research is supported by COST Action CM1406 (EPI-CHEM) (to M.B.), a European Research Council Advanced Grant under the European Community’s Seventh Framework Programme EPI-NORC project (to M.E.), RecerCaixa Foundation (to M.B.), Federación Española de Enfermedades Raras, Federación Española de Enfermedades Neuromusculares, Fundación Isabel Gemio (to M.B.), Spanish Association Against Cancer (AECC) (to M.B.), the Spanish Ministry of Health (FIS) (to M.B.) and Ministerio de Economía y Competitividad (MINECO) (to M.E.). D.J.H. has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 642934.

References

1. Djebali S et al. 2012 Landscape of transcription in human cells. Nature 489, 101 – 108. (doi:10.1038/nature11233)
2. Orom UA, Shiekhattar R. 2013 Long noncoding RNAs usher in a new era in the biology of enhancers. Cell 154, 1190 – 1193. (doi:10.1016/j.cell.2013.08.038)
3. Esteller M. 2011 Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861 – 874. (doi:10.1038/nrg3074)
4. Iyer MK et al. 2015 The landscape of long noncoding IncRNAs in the human transcriptome. Nat. Genet. 47, 199 – 208. (doi:10.1038/nrg3192)
5. Khorkova O, Hsiao J, Wahlestedt C. 2015 Basic biology and therapeutic implications of IncRNA. Adv. Drug Deliv. Rev. 87, 15 – 24. (doi:10.1016/j.addr.2015.05.002)
6. Wang KC, Chang HY. 2011 Molecular mechanisms of long noncoding RNAs. Mol. Cell 43, 904 – 914. (doi:10.1016/j.molcel.2011.08.018)
7. Rinn JL, Chang HY. 2012 Genome regulation by long noncoding RNAs. Annu. Rev. Biochem. 81, 145 – 166. (doi:10.1146/annurev-biochem-051410-092902)
8. Engert JM, Ollikainen N, Gutmann M. 2016 Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression. Nat. Rev. Mol. Cell Biol. 17, 756 – 770. (doi:10.1038/nrm.2016.126)
9. Davidovich C, Cech TR. 2015 The recruitment of chromatin modifiers by long noncoding RNAs: lessons from PRC2. RNA 21, 2007 – 2022. (doi:10.1261/rna.053918.115)
10. Wutz A, Rasmussen TP, Jaenisch R. 2002 Chromosomal silencing and localization are mediated by different domains of Xist RNA. Nat. Genet. 30, 167 – 174. (doi:10.1038/ng820)
11. Hasegawa Y, Brockdoff N, Kawano S, Tsutui K, Tsutui K, Nakagawa S. 2010 The matrix protein hnRNP U is required for chromosomal localization of Xist RNA. Dev. Cell 19, 469 – 476. (doi:10.1016/j.devcel.2010.08.006)
12. Lan T, Chang L, Wu L, Yuan Y. 2016 Downregulation of ZEB2-AS1 decreased tumor growth and metastasis in hepatocellular carcinoma. Mol. Med. Rep. 14, 4606 – 4612. (doi:10.3892/mmr.2016.8386)
13. de Lera AR, Ganesan A. 2016 Epigenetic polypharmacology: from combination therapy to multitargeted drugs. Clin. Epigenetics 8, 7874. (doi:10.1186/s13384-016-0271-9)
14. Delgado-Mores M, Gagnier-Boxa R, Esteller M, Berdasco M. 2017 Epigenetic mechanisms during ageing and neurogenesis as novel therapeutic avenues in human brain disorders. Clin. Epigenetics 9, 1194. (doi:10.1186/s13148-017-0365-z)
15. Mchugh CA et al. 2015 The Xist IncRNA directly interacts with SHARP to silence transcription through HDAC3. Nature 521, 232 – 236. (doi:10.1038/nature14443)
16. Rinn JL et al. 2007 Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129, 1311 – 1323. (doi:10.1016/j.cell.2007.05.022)
17. Huang P, Plass C, Chen C-S. 2011 Effects of histone deacetylase inhibitors on modulating H3K4 methylation marks—a novel cross-talk mechanism between histone-modifying enzymes. Mol. Cell. Pharmacol. 3, 39 – 43.
18. Zhao J et al. 2010 Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol. Cell 40, 939 – 953. (doi:10.1016/j.molcel.2010.12.011)
27. Kornienko AE, Dotter CP, Guenzl PM, Gisslinger H, Bose DA, Donahue G, Reinberg D, Shiekhattar R, Khorkova O, Hsiao J, Wahlestedt C. 2013
26. Nagano T, Mitchell JA, Sanz LA, Pauler FM, Barlow MD, Komorowski J, Lan F, Shi Y, Segal E, Chang HY. 2010 Long noncoding RNA programs
25. Mohammad F, Mondal T, Guseva N, Pandey GK, Pang KC, Frith MC, Mattick JS. 2006 Rapid evolution of noncoding RNA mediates transcriptional silencing through chromatin-level regulation. Mol. Cell 32, 232 – 246. (doi:10.1016/j.molcel.2008.08.022)
24. Wang X, Arii S, Song X, Reichart D, Du K, Tempst P, Rosenfeld MG, Glass CK. 2010 Induced mRmRNAs allosterically modify RNA binding proteins to cis to inhibit transcription. Nature 454, 126 – 130. (doi:10.1038/nature06992)
23. Kornblihtt AR, Schor IE, Allo ´ M, Dujardin G, Petrillo M, Calabrese JM, Magnuson T, Heard E, Chang HY. 2011 Competition between H3K4me3 and H3K27me3 to promote tumor cell invasion and metastasis. Proc. Natl Acad. Sci. USA 108, 120 – 124. (doi:10.1073/pnas.1016069)
22. Kornblihtt AR, Schor IE, Allo ´ M, Dujardin G, Petrillo M, Calabrese JM, Magnuson T, Heard E, Chang HY. 2011.03.004
21. Ishizuka A, Hasegawa Y, Ishida K, Yanaka K, Ishikawa H, Yagita H, Kiyotani K, Tani A, Nakamura K, Nakashima K, et al. 2011 Long non-coding RNA regulates synaptogenesis by modulating gene expression. Cell 144, 16 – 26. (doi:10.1016/j.cell.2010.11.056)
20. Luco RF, Allo M, Schor IE, Kombriltb AR, Mistelí T. 2011 The Xist lncRNA exploits long non-coding RNA mediated transcriptional repression. Nature 477, 369 – 373. (doi:10.1038/nature10342)
19. Aquilina V, Zhou MM, Walsh MJ. 2011 Long noncoding RNA, polycym, and the ghosts haunting INK4a-ARF-INK4a expression. Cancer Res. 71, 5365 – 5369. (doi:10.1158/0008-5472.CAN-10-4379)
18. Komienko AE, Dotter CP, Guenzl PM, Gisslinger H, Bose DA, Donahue G, Reinberg D, Shiekhattar R, Khorkova O, Hsiao J, Wahlestedt C. 2013
17. Kornblihtt AR, Schor IE, Allo ´ M, Dujardin G, Petrillo M, Calabrese JM, Magnuson T, Heard E, Chang HY. 2011 Competition between H3K4me3 and H3K27me3 to promote tumor cell invasion and metastasis. Proc. Natl Acad. Sci. USA 108, 120 – 124. (doi:10.1073/pnas.1016069)
16. Ishizuka A, Hasegawa Y, Ishida K, Yanaka K, Ishikawa H, Yagita H, Kiyotani K, Tani A, Nakamura K, Nakashima K, et al. 2011 Long non-coding RNA regulates synaptogenesis by modulating gene expression. Cell 144, 16 – 26. (doi:10.1016/j.cell.2010.11.056)
15. Luco RF, Allo M, Schor IE, Kombriltb AR, Mistelí T. 2011 The Xist lncRNA exploits long non-coding RNA mediated transcriptional repression. Nature 477, 369 – 373. (doi:10.1038/nature10342)
14. Ishizuka A, Hasegawa Y, Ishida K, Yanaka K, Nakashima K, et al. 2011 Long non-coding RNA regulates synaptogenesis by modulating gene expression. Cell 144, 16 – 26. (doi:10.1016/j.cell.2010.11.056)
13. Komienko AE, Dotter CP, Guenzl PM, Gisslinger H, Bose DA, Donahue G, Reinberg D, Shiekhattar R, Khorkova O, Hsiao J, Wahlestedt C. 2013
12. Kornblihtt AR, Schor IE, Allo ´ M, Dujardin G, Petrillo M, Calabrese JM, Magnuson T, Heard E, Chang HY. 2011 Competition between H3K4me3 and H3K27me3 to promote tumor cell invasion and metastasis. Proc. Natl Acad. Sci. USA 108, 120 – 124. (doi:10.1073/pnas.1016069)
11. Ishizuka A, Hasegawa Y, Ishida K, Yanaka K, Nakashima K, et al. 2011 Long non-coding RNA regulates synaptogenesis by modulating gene expression. Cell 144, 16 – 26. (doi:10.1016/j.cell.2010.11.056)
10. Luco RF, Allo M, Schor IE, Kombriltb AR, Mistelí T. 2011 The Xist lncRNA exploits long non-coding RNA mediated transcriptional repression. Nature 477, 369 – 373. (doi:10.1038/nature10342)
9. Ishizuka A, Hasegawa Y, Ishida K, Yanaka K, Nakashima K, et al. 2011 Long non-coding RNA regulates synaptogenesis by modulating gene expression. Cell 144, 16 – 26. (doi:10.1016/j.cell.2010.11.056)
8. Komienko AE, Dotter CP, Guenzl PM, Gisslinger H, Bose DA, Donahue G, Reinberg D, Shiekhattar R, Khorkova O, Hsiao J, Wahlestedt C. 2013
7. Kornblihtt AR, Schor IE, Allo ´ M, Dujardin G, Petrillo M, Calabrese JM, Magnuson T, Heard E, Chang HY. 2011 Competition between H3K4me3 and H3K27me3 to promote tumor cell invasion and metastasis. Proc. Natl Acad. Sci. USA 108, 120 – 124. (doi:10.1073/pnas.1016069)
6. Ishizuka A, Hasegawa Y, Ishida K, Yanaka K, Nakashima K, et al. 2011 Long non-coding RNA regulates synaptogenesis by modulating gene expression. Cell 144, 16 – 26. (doi:10.1016/j.cell.2010.11.056)
5. Komienko AE, Dotter CP, Guenzl PM, Gisslinger H, Bose DA, Donahue G, Reinberg D, Shiekhattar R, Khorkova O, Hsiao J, Wahlestedt C. 2013
4. Komienko AE, Dotter CP, Guenzl PM, Gisslinger H, Bose DA, Donahue G, Reinberg D, Shiekhattar R, Khorkova O, Hsiao J, Wahlestedt C. 2013
3. Komienko AE, Dotter CP, Guenzl PM, Gisslinger H, Bose DA, Donahue G, Reinberg D, Shiekhattar R, Khorkova O, Hsiao J, Wahlestedt C. 2013
2. Komienko AE, Dotter CP, Guenzl PM, Gisslinger H, Bose DA, Donahue G, Reinberg D, Shiekhattar R, Khorkova O, Hsiao J, Wahlestedt C. 2013
1. Komienko AE, Dotter CP, Guenzl PM, Gisslinger H, Bose DA, Donahue G, Reinberg D, Shiekhattar R, Khorkova O, Hsiao J, Wahlestedt C. 2013
61. Ge XS, Ma HJ, Zheng XH, Ruan HL, Liao XY, Xue WQ, Chen Y-B, Zhang Y, Jia WH. 2013 HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits Wii-1 expression and activates Wnt pathway. Cancer Res. 104, 1675 – 1682. (doi:10.1111/cac.12296)

62. Li X, Lu H, Fan G, He M, Sun Y, Xu K, Shi F. 2017 A novel interplay between HOTAIR and DNA methylation in osteosarcoma cells indicates a new therapeutic strategy. J. Cancer Res. Clin. Oncol. 143, 2189 – 2200. (doi:10.1007/s00432-017-2478-3)

63. Niinuma T et al. 2012 Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res. 72, 1126 – 1136. (doi:10.1158/0008-5472.CAN-11-1803)

64. Kogo R et al. 2017 The noncoding RNA MALAT1 transcriptionally regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 71, 6520 – 6526. (doi:10.1158/0008-5472.CAN-17-0211)

65. Geng YJ, Xie SL, Li Q, Ma J, Wang GF. 2011 Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J. Int. Med. Res. 39, 2119 – 2128. (doi:10.1177/0300060511409008)

66. Yang Z, Zhou L, Wu L-M, Lai M-C, Xie H-Y, Zhang F, Battistelli C et al. 2017 EZH2 dependent manner. Cell 173, 1180 – 1189. (doi:10.1016/j.cell.2017.04.040)

67. Jen J, Tang Y-A, Lu Y-H, Lin C-C, Lai W-W, Wang Y-C. 2017 Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression. Mol. Cancer 16, 440. (doi:10.1186/s12943-017-0674-z)

68. Fan Y, Shen B, Tan M, Xu Q, Yin J, Zhang F, Liu Y. 2014 TGF-β-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin. Cancer Res. 20, 1531 – 1541. (doi:10.1158/1078-0432.CCR-13-1455)

69. Hirata H, Hino Y, Shahyari V, Deng G, Nakajima K, Tabatabai ZI, Ishii N, Dahia R. 2015 Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through EZH2 and interacts with miR-205. Cancer Res. 75, 1322 – 1331. (doi:10.1158/0008-5472.CAN-14-2931)

70. Huang W. 2017 Long noncoding RNA HOTAIR is a potential target for the treatment of cisplatin resistant ovarian cancer. Ann. Surg. Oncol. 24, 3617 – 3624. (doi:10.1245/s10434-017-5940-5)

71. Wang Y, Wang H, Song T, Zou Y, Jiang J, Fang L, et al. 2016 The Snail repressor recruits EZH2 to specific genomic sites through the interaction of EZH2 with suz12. Cancer Cell 31, 537 – 546. (doi:10.1016/j.cell.2016.04.025)

72. LincRNA-p21 contributes to cisplatin resistance of human lung cancer cells. Cancer Res. 73, 1180 – 1189. (doi:10.1158/0008-5472.CAN-12-2830)

73. Gutschner T et al. 2013 The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 73, 1180 – 1189. (doi:10.1158/0008-5472.CAN-12-2830)
antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial—mesenchymal transition. Genes Dev. **22**, 756 – 769. (doi:10.1101/gad.455708)

100. Hsiao J et al. 2016 Upregulation of haploinsufficient gene expression in the brain by targeting a long non-coding RNA improves seizure phenotype in a model of dravet syndrome. EBioMedicine **9**, 257 – 277. (doi:10.1016/j.ebiom.2016.05.011)

101. Corey DR. 2016 Synthetic nucleic acids and treatment of neurological diseases. *JAMA Neurol.* **73**, 1238 – 1242. (doi:10.1001/jamaneurol.2016.2089)

102. Cano-Rodriguez D, Rots MG. 2016 Epigenetic editing: on the verge of reprogramming gene expression at will. *Curr. Genet. Med. Rep.* **4**, 170 – 179. (doi:10.1007/s40142-016-0104-3)